Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ceralasertib by AstraZeneca for Solid Tumor: Likelihood of Approval
Ceralasertib is under clinical development by AstraZeneca and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
Ceralasertib by AstraZeneca for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Ceralasertib is under clinical development by AstraZeneca and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative...
Ceralasertib by AstraZeneca for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Ceralasertib is under clinical development by AstraZeneca and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData,...
Ceralasertib by AstraZeneca for Metastatic Colorectal Cancer: Likelihood of Approval
Ceralasertib is under clinical development by AstraZeneca and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Ceralasertib by AstraZeneca for Solid Tumor: Likelihood of Approval
Ceralasertib is under clinical development by AstraZeneca and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of AstraZeneca's Ceralasertib?
Ceralasertib is a small molecule commercialized by AstraZeneca, with a leading Phase III program in Non-Small Cell Lung Cancer. According...
Risk adjusted net present value: What is the current valuation of AstraZeneca's Ceralasertib?
Ceralasertib is a small molecule commercialized by AstraZeneca, with a leading Phase III program in Non-Small Cell Lung Cancer. According...